Lotus Pharmaceuticals Stock Probability Of Bankruptcy
| LTUS Stock | USD 0.01 0 28.57% |
Lotus |
Lotus Pharmaceuticals Company probability of financial unrest Analysis
Lotus Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Lotus Pharmaceuticals Probability Of Bankruptcy | Less than 42% |
Most of Lotus Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lotus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Lotus Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Lotus Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Lotus Pharmaceuticals financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Lotus Pharmaceuticals has a Probability Of Bankruptcy of 42.0%. This is 15.88% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 5.45% lower than that of the firm.
Lotus Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lotus Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lotus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceuticals by comparing valuation metrics of similar companies.Lotus Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
Lotus Fundamentals
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 762.17 K | |||
| Shares Outstanding | 27.82 M | |||
| Price To Earning | 0.18 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 72.7 M | |||
| Gross Profit | 39.78 M | |||
| EBITDA | 10.31 M | |||
| Net Income | 14.42 M | |||
| Cash And Equivalents | 158.91 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5.24 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 0.53 X | |||
| Book Value Per Share | 3.58 X | |||
| Cash Flow From Operations | 26.78 M | |||
| Earnings Per Share | 0.06 X | |||
| Number Of Employees | 233 | |||
| Beta | 0.51 | |||
| Market Capitalization | 834.49 K | |||
| Total Asset | 103.18 M | |||
| Retained Earnings | 65 M | |||
| Working Capital | (6 M) | |||
| Current Asset | 8 M | |||
| Current Liabilities | 14 M | |||
| Net Asset | 103.18 M |
About Lotus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lotus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lotus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lotus Pharmaceuticals' short interest history, or implied volatility extrapolated from Lotus Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lotus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Lotus Pink Sheet analysis
When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |